We use cookies
BostonGene logo

Drug repurposing

Maximizing the potential of the existing drug portfolio by discovering beneficial drug-disease matches:
✔ For already approved drugs: Identification of a broader patient population
✔ For failed drug candidates: Search for new ways of therapeutic use

BostonGene is a recognized
leader in drug repurposing AI

According to GlobalData 2023 report
Bubble size = patent volumes between 2020 and 2022
‘Application diversity’ measures the number of applications identified for each patent.
‘Geographic reach’ refers to the number of countries each patent is registered in.

Source: GlobalData Patent Analytics

Benefits of drug repurposing compared to de novo drug development

Accelerated drug approval
2x shorter development lifecycle1
Lower cost
10x cost reduction to enter the market1
Reduced risk
Lower safety and pharmacokinetic uncertainty2
  1. Nosengo, N. Nature (2016)
  2. Ashburn, T., Thor, K. Nat Rev Drug Discov (2004)

BostonGene’s solutions for drug repurposing

BostonGene leverages a unique combination of comprehensive molecular and clinical databases, along with analytical and bioinformatics expertise, for the identification of potential new drug indications.
Target identification
Systematic analysis of disease biology:
Target prevalence by:

  • Cancer type
  • Tissue type
  • Cell type
  • Cancer cell vs TME
  • Signaling pathways analysis
Unmet need identification
Assessment of unmet medical need based on:
  • Clinical practice guidelines
  • FDA-approved therapies
  • Clinical outcomes
  • Ongoing clinical trials
Indication options
Suitability of a potential indication based on:
Market size, including the potential number of patients:

  • Current market trends
  • Competitive landscape
Helpful resources
Analytical and clinical capabilities Clinical research solutions Laboratory capabilities Solutions for patients stratification and research Discovery solutions sample requirements